What Does Ulceration of a Melanoma Mean for Prognosis?

Advances in Surgery

Volumn 45, Issue 1, 2011, Pages 225-236

  Callender, Glenda G ^a   McMasters, Kelly M ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; CANCER STAGING; GENETICS; HUMAN; KAPLAN MEIER METHOD; MELANOMA; MORTALITY; PATHOLOGY; PROGNOSIS; REVIEW; SENTINEL LYMPH NODE BIOPSY; SKIN TUMOR; ULCER;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; HUMANS; INTERFERON ALFA-2B; KAPLAN-MEIER ESTIMATE; MELANOMA; NEOPLASM STAGING; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; ULCER;

EID: 79961191206     PISSN: 00653411     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yasu.2011.03.002     Document Type: Review

References (31)

1. AJCC cancer staging manual 2002, Springer, New York. 6th edition. F.L. Greene, D.L. Page, I.D. Fleming (Eds.).
2. Allen A.C., Spitz S. Malignant melanoma. A clinicopathological analysis of the criteria for diagnosis and prognosis. Cancer 1953, 6:1-45.
3. Thompkins V.N. Cutaneous melanoma: ulceration as a prognostic sign. Cancer 1953, 6:1215-1218.
4. Cochran A.J. Histology and prognosis in malignant melanoma. J Pathol 1969, 97:459-468.
5. Franklin J.D., Reynolds V.H., Page D.L. Cutaneous melanoma: a twenty-year retrospective study with clinicopathologic correlation. Plast Reconstr Surg 1975, 56:277-285.
6. Huvos A.G., Shah J.P., Mike V. Prognostic factors in cutaneous malignant melanoma. A comparative study of long term and short term survivors. Hum Pathol 1974, 5:347-357.
7. Balch C.M., Wilkerson J.A., Murad T.M., et al. The prognostic significance of ulceration of cutaneous melanoma. Cancer 1980, 45:3012-3017.
8. Balch C.M., Murad T.M., Soong S.J., et al. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg 1978, 188:732-742.
9. Sarpa H.G., Reinke K., Shaikh L., et al. Prognostic significance of extent of ulceration in primary cutaneous melanoma. Am J Surg Pathol 2006, 30:1396-1400.
10. Eigentler T.K., Buettner P.G., Leiter U., et al. Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry. J Clin Oncol 2004, 22:4376-4383.
11. AJCC cancer staging manual 2009, Springer, New York. 7th edition. S.B. Edge, D.R. Byrd, C.C. Compton (Eds.).
12. Balch C.M., Gershenwald J.E., Soong S.J., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206.
13. Gershenwald J.E., Thompson W., Mansfield P.F., et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma. J Clin Oncol 1999, 17:976-983.
14. Wagner J.D., Gordon M.S., Chuang T.Y., et al. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 2000, 89:453-462.
15. Gershenwald J.E., Tseng C.H., Thompson W., et al. Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery 1998, 124:203-210.
16. Porter G.A., Ross M.I., Berman R.S., et al. Significance of multiple nodal basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy. Ann Surg Oncol 2000, 7:256-261.
17. McMasters K.M., Wong S.L., Edwards M.J., et al. Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery 2001, 130:151-156.
18. McMasters K.M., Edwards M.J., Ross M.I., et al. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma. Ann Surg 2010, 252:460-466.
19. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996, 14:7-17.
20. Kirkwood J.M., Ibrahim J.G., Sondak V.K., et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of Intergroup Trial E1690/S9111/C9190. J Clin Oncol 2000, 18:2444-2458.
21. Kirkwood J.M., Ibrahim J.G., Sosman J.A., et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of Intergroup Trial E1694/S9512/C509801. J Clin Oncol 2001, 19:2370-2380.
22. Kirkwood J.M., Manola J., Ibrahim J., et al. A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004, 10:1670-1677.
23. McMasters K.M., Ross M.I., Reintgen D.S., et al. Final results of the Sunbelt Melanoma Trial. J Clin Oncol 2008, 26:15s. [abstract: 9003].
24. Eggermont A.M., Suciu S., Testori A., et al. Ulceration of primary melanoma and responsiveness to adjuvant interferon therapy: analysis of the adjuvant trials EORTC18952 and EORTC18991 in 2,644 patients. J Clin Oncol 2009, 27:15s. [abstract: 9007].
25. Spatz A., Batist G., Eggermont A.M. The biology behind prognostic factors of cutaneous melanoma. Curr Opin Oncol 2010, 22:163-168.
26. Mascaro J.M., Castro J., Castel T., et al. Why do melanomas ulcerate?. J Cutan Pathol 1984, 11:269-273.
27. Azzola M.F., Shaw H.M., Thompson J.F., et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 2003, 97:1488-1498.
28. Kashani-Sabet M., Sagebiel R.W., Ferreira C.M., et al. Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J Clin Oncol 2002, 20:1826-1831.
29. Kashani-Sabet M., Shaikh L., Miller J.R., et al. NF-kB in the vascular progression of melanoma. J Clin Oncol 2004, 22:617-623.
30. Fukunaga-Kalabis M., Santiago-Walker A., Herlyn M. Matricellular proteins produced by melanocytes and melanomas: in search for functions. Cancer Microenviron 2008, 1:93-102.
31. Ellerhorst J.A., Greene V.R., Ekmekcioglu S., et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 2011, 17:229-235.